Changes for page Jubilant Pharmova Limited
Last modified by Asif Farooqui on 2021/06/16 06:17
Change comment:
There is no comment for this version
Summary
-
Page properties (2 modified, 0 added, 0 removed)
-
Attachments (0 modified, 1 added, 0 removed)
-
Objects (0 modified, 1 added, 0 removed)
Details
- Page properties
-
- Tags
-
... ... @@ -1,0 +1,1 @@ 1 +IN:JUBLPHARMA - Content
-
... ... @@ -22,6 +22,9 @@ 22 22 Jubilant Pharmova Limited has a team of around 7,700 multicultural people across the globe and is committed to delivering value to its customers in over 100 countries. The Company is well recognized as a ‘Partner of Choice’ by leading pharmaceuticals and life sciences companies worldwide. 23 23 24 24 25 +[[image:JUBLPHARMA1.png]] 26 + 27 + 25 25 = Business Segments = 26 26 27 27 == Pharmaceuticals == ... ... @@ -53,7 +53,7 @@ 53 53 One of the market leaders in the United States, based on market share of several key products 54 54 55 55 56 -== Contract R esearch andDevelopmentServices ==59 +== Contract R&D Services == 57 57 58 58 Jubilant Biosys Ltd is a part of the Jubilant Pharmova family of companies with R&D centers in India and business offices in Asia and North America. With its global reach, Jubilant Biosys provides comprehensive drug discovery services and contract research services–from target discovery to candidate selection and with flexible business models (FFS, FTE and risk shared)–in partnership with leading worldwide healthcare companies. {{footnote}}https://www.jubilantbiosys.com/about-us/company-overview/{{/footnote}} 59 59 ... ... @@ -73,9 +73,9 @@ 73 73 * Synthetic & Developmental Chemistry 74 74 * Pharmacology 75 75 76 - 77 77 Jubilant Biosys collaborates with the world’s leading pharmaceutical, biotech companies, academic institutions and research foundations. 78 78 81 +{{putFootnotes/}} 79 79 80 80 == Proprietary Novel Drugs == 81 81 ... ... @@ -106,6 +106,9 @@ 106 106 The global crop protection chemicals market size was US$ 58.4 billion in 2019 and is anticipated to expand at a CAGR of 3.3% from 2020 to 2027. Greater emphasis on high crop output to counter food security is the key growth driver. 107 107 108 108 112 +[[image:JUBLPHARMA2.png]] 113 + 114 + 109 109 = Financial Overview = 110 110 111 111 ... ... @@ -134,6 +134,9 @@ 134 134 The Drug Discovery & Development Solutions (DDDS) segment includes its Drug Discovery Services (Jubilant Biosys Limited and Jubilant Chemsys Limited) & Proprietary Drug Discovery (Jubilant Therapeutics Inc.) businesses. Revenues in FY 2020 were at Rs 2,615 million as compared to Rs 2,168 million in the previous year, up 21% YoY. 135 135 136 136 143 +[[image:JUBLPHARMA3.png]] 144 + 145 + 137 137 == FY21 results == 138 138 139 139
- JUBLPHARMA2.png
-
- Author
-
... ... @@ -1,0 +1,1 @@ 1 +XWiki.AsifF - Size
-
... ... @@ -1,0 +1,1 @@ 1 +194.2 KB - Content
- XWiki.XWikiComments[0]
-
- Author
-
... ... @@ -1,0 +1,1 @@ 1 +XWiki.AsifF - Comment
-
... ... @@ -1,0 +1,2 @@ 1 +Recent investor presentation 2 +https://www.jubilantpharmova.com/Uploads/image/1654imguf_JLL-InvestorPresentationNovember2020.pdf - Date
-
... ... @@ -1,0 +1,1 @@ 1 +2021-06-15 06:06:08.502